Extracellular vesicle therapeutics in Alzheimer's disease: mechanisms, progress, and prospects
Fang Y., Hao X., Fang B.
Narrative Review on Neuroinflammation, published in Extracell Vesicles Circ Nucl Acids (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Extracell Vesicles Circ Nucl Acids (2026)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41983050
- PMCID
- PMC13074295
- DOI
- 10.20517/evcna.2025.158
- Citations
- 1
Abstract (original English)
Alzheimer's disease (AD) is the most prevalent neurodegenerative disorder worldwide, characterized by progressive cognitive decline and a current lack of effective curative treatments. In recent years, extracellular vesicle (EV) therapies have emerged as a cutting-edge approach in AD research due to their unique biological properties. This review systematically examines the role of EVs in the pathogenesis of AD, including their cellular origins and functional attributes. We detail the molecular mechanisms mediated by EVs that influence AD progression and summarize the latest advancements in EV-based therapeutic strategies. Additionally, the review addresses the challenges faced in translating these therapies from bench to bedside, such as standardization, delivery optimization, and safety concerns. Future research directions are discussed to foster the development of innovative and effective treatments for AD. By providing a comprehensive overview, this article aims to lay a theoretical foundation and offer valuable insights for the advancement of novel therapeutic interventions targeting AD.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.
Related research
- Level ASystematic ReviewPubMed
Adipose-Derived Stem Cells in Traumatic Brain Injury: A Systematic Review of Preclinical Studies.
Systematic Review on Neuroinflammation, published in Tissue Eng Regen Med (2026) — summary generated from the PubMed abstract.
- 2026
Tissue Eng Regen Med - Level ASystematic ReviewPubMed
The use of cellular therapies for trigeminal neuralgia: a systematic review of behavioral and molecular outcomes.
Systematic Review with a reported sample of 8 on Neuroinflammation, published in Neurosurg Rev (2026) — summary generated from the PubMed abstract.
- 2026
- n = 8
Neurosurg Rev - Level ASystematic ReviewEurope PMC
Factor XII-A New Therapeutic Target? A Systematic Review
Systematic Review on Cardiovascular Disease, Neuroinflammation, published in Int J Mol Sci (2026) — summary generated from the PubMed abstract.
- 2026
Int J Mol Sci1 citations - Level ASystematic ReviewEurope PMC
Efficacy of Exosome-Based Therapies for Skin Rejuvenation: A Systematic Review of Human Studies
Systematic Review on Neuroinflammation, Skin Aging, published in Cureus (2026) — summary generated from the PubMed abstract.
- 2026
Cureus - Level ASystematic ReviewEurope PMC
Harnessing exosomes in dry eye disease: a triple threat approach
Systematic Review on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in BMC Ophthalmol (2026) — summary generated from the PubMed abstract.
- 2026
BMC Ophthalmol - Level ASystematic ReviewEurope PMC
Safety and Efficacy of Mesenchymal Stem Cell Therapy in Multiple System Atrophy: Systematic Review
Systematic Review with a reported sample of 123 on Neuroinflammation, Chronic Inflammation, Immune Modulation, published in Biologics (2026) — summary generated from the PubMed abstract.
- 2026
- n = 123
Biologics